Phase II Evaluation of Sorafenib in Advanced and Metastatic Squamous Cell Carcinoma of the Head and Neck: Southwest Oncology Group Study S0420

Journal of Clinical Oncology

Volumn 28, Issue 20, 2010, Pages 3330-3335

  Williamson, Stephen K ^a   Moon, James ^a   Huang, Chao H ^a   Guaglianone, Perry P ^a   LeBlanc, Michael ^a   Wolf, Gregory T ^a   Urba, Susan G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; ESOPHAGITIS; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; LETHARGY; LEUKOPENIA; LUNG EMBOLISM; MALAISE; MALE; METASTASIS; MOUTH PAIN; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; SOMNOLENCE; SQUAMOUS CELL CARCINOMA; STOMATITIS; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; AGED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG SCREENING; HEAD AND NECK TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; DRUG EVALUATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PYRIDINES;

EID: 77954754601     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.6834     Document Type: Article

References (35)

1. Forastiere AA, Leong T, Rowinsky E, et al: Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 19:1088-1095, 2001 (Pubitemid 32176285)
2. Forastiere AA, Metch B, Schuller DE, et al: Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study. J Clin Oncol 10:1245-1251, 1992
3. Samlowski WE, Gundacker H, Kuebler JP, et al: Evaluation of gemcitabine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A Southwest Oncology Group phase II study. Invest New Drugs 19:311-315, 2001 (Pubitemid 32782971)
4. Samlowski WE, Lew D, Kuebler PJ, et al: Evaluation of Tomudex in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A Southwest Oncology Group study. Invest New Drugs 16:271-274, 1998 (Pubitemid 29201747)
5. Smith RE, Lew D, Rodriguez GI, et al: Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck: A phase II Southwest Oncology Group study. Invest New Drugs 14:403-407, 1996
6. Samlowski WE, Moon J, Kuebler JP, et al: Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group Phase II study. Cancer Invest 25:182-188, 2007 (Pubitemid 47164860)
7. Worden FP, Moon J, Samlowski W, et al: A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007. Cancer 107:319-327, 2006 (Pubitemid 44036561)
8. Salomon DS, Brandt R, Ciardiello F, et al: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232, 1995
9. Alroy I, Yarden Y: The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 410:83-86, 1997 (Pubitemid 27283389)
10. Lewis TS, Shapiro PS, Ahn NG: Signal transduction through MAP kinase cascades. Adv Cancer Res 74:49-139, 1998 (Pubitemid 28193546)
11. Campbell SL, Khosravi-Far R, Rossman KL, et al: Increasing complexity of Ras signaling. Oncogene 17:1395-1413, 1998 (Pubitemid 28458409)
12. Chong H, Vikis HG, Guan KL: Mechanisms of regulating the Raf kinase family. Cell Signal 15:463-469, 2003 (Pubitemid 36292166)
13. Hoa M, Davis SL, Ames SJ, et al: Amplification of wild-type K-ras promotes growth of head and neck squamous cell carcinoma. Cancer Res 62:7154-7156, 2002 (Pubitemid 36025228)
14. Gold KA, Kim ES: Role of molecular markers and gene profiling in head and neck cancers. Curr Opin Oncol 21:206-211, 2009
15. Neuchrist C, Erovic BM, Handisurya A, et al: Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck. Head Neck 25:464-474, 2003 (Pubitemid 36577031)
16. Neuchrist C, Erovic BM, Handisurya A, et al: Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck. Laryngoscope 111:1834-1841, 2001
17. Thomas GR, Nadiminti H, Regalado J: Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol 86:347-363, 2005 (Pubitemid 41746374)
18. Bayer Pharmaceuticals: Investigator's Brochure BAY 43-9006/Raf Kinase Inhibitor, Version No. 4.1. August 21, 2003
19. Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109, 2004 (Pubitemid 39331023)
20. Mendelsohn J: Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20:1S-13S, 2002 (suppl 18)
21. Strumberg D, Richly H, Hilger RA, et al: Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965-972, 2005 (Pubitemid 46202316)
22. Strumberg D, Voliotis D, Moeller JG, et al: Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther 40:580-581, 2002
23. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. NEJM 356:125-134, 2007 (Pubitemid 46089673)
24. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. NEJM 359:378-390, 2008
25. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
26. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
27. Brookmeyer R, Crowley J: A confidence interval for the median survival time. Biometrics 38:29-41, 1982
28. Vermorken JB, Trigo J, Hitt R, et al: Openlabel, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25:2171-2177, 2007 (Pubitemid 46954639)
29. Elser C, Siu LL, Winquist E, et al: Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 25:3766-3773, 2007 (Pubitemid 47372619)
30. Plastaras JP, Kim SH, Liu YY, et al: Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res 67:9443-9454, 2007 (Pubitemid 47535934)
31. Molhoek KR, Brautigan DL, Slingluff CL Jr: Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J Transl Med 3:39, 2005
32. Jane EP, Premkumar DR, Pollack IF: Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J Pharmacol Exp Ther 319:1070-1080, 2006
33. Yu C, Friday BB, Lai JP, et al: Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: Induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer Ther 5:2378-2387, 2006 (Pubitemid 44530475)
34. Heim M, Scharifi M, Zisowsky J, et al: The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anticancer Drugs 16:129-136, 2005 (Pubitemid 40250607)
35. Heim M, Sharifi M, Hilger RA, et al: Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006. Int J Clin Pharmacol Ther 41:616-617, 2003